Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 4
2013 4
2014 3
2015 2
2017 1
2018 1
2020 0
Text availability
Article attribute
Article type
Publication date

Search Results

14 results
Results by year
Filters applied: . Clear all
Page 1
Molecular profiling and combinatorial activity of CCT068127: a potent CDK2 and CDK9 inhibitor.
Whittaker SR, Barlow C, Martin MP, Mancusi C, Wagner S, Self A, Barrie E, Te Poele R, Sharp S, Brown N, Wilson S, Jackson W, Fischer PM, Clarke PA, Walton MI, McDonald E, Blagg J, Noble M, Garrett MD, Workman P. Whittaker SR, et al. Mol Oncol. 2018 Mar;12(3):287-304. doi: 10.1002/1878-0261.12148. Epub 2018 Jan 28. Mol Oncol. 2018. PMID: 29063678 Free PMC article.
CDK1 structures reveal conserved and unique features of the essential cell cycle CDK.
Brown NR, Korolchuk S, Martin MP, Stanley WA, Moukhametzianov R, Noble MEM, Endicott JA. Brown NR, et al. Nat Commun. 2015 Apr 13;6:6769. doi: 10.1038/ncomms7769. Nat Commun. 2015. PMID: 25864384 Free PMC article.
Structural characterization of the cyclin-dependent protein kinase family.
Endicott JA, Noble ME. Endicott JA, et al. Biochem Soc Trans. 2013 Aug;41(4):1008-16. doi: 10.1042/BST20130097. Biochem Soc Trans. 2013. PMID: 23863171 Review.
The structural basis for control of eukaryotic protein kinases.
Endicott JA, Noble ME, Johnson LN. Endicott JA, et al. Annu Rev Biochem. 2012;81:587-613. doi: 10.1146/annurev-biochem-052410-090317. Epub 2012 Apr 5. Annu Rev Biochem. 2012. PMID: 22482904 Review.
Perspective of cyclin-dependent kinase 9 (CDK9) as a drug target.
Krystof V, Baumli S, F├╝rst R. Krystof V, et al. Curr Pharm Des. 2012;18(20):2883-90. doi: 10.2174/138161212800672750. Curr Pharm Des. 2012. PMID: 22571657 Free PMC article. Review.
Cyclin-Dependent Kinase (CDK) Inhibitors: Structure-Activity Relationships and Insights into the CDK-2 Selectivity of 6-Substituted 2-Arylaminopurines.
Coxon CR, Anscombe E, Harnor SJ, Martin MP, Carbain B, Golding BT, Hardcastle IR, Harlow LK, Korolchuk S, Matheson CJ, Newell DR, Noble ME, Sivaprakasam M, Tudhope SJ, Turner DM, Wang LZ, Wedge SR, Wong C, Griffin RJ, Endicott JA, Cano C. Coxon CR, et al. J Med Chem. 2017 Mar 9;60(5):1746-1767. doi: 10.1021/acs.jmedchem.6b01254. Epub 2017 Feb 14. J Med Chem. 2017. PMID: 28005359 Free PMC article.
Identification and Characterization of an Irreversible Inhibitor of CDK2.
Anscombe E, Meschini E, Mora-Vidal R, Martin MP, Staunton D, Geitmann M, Danielson UH, Stanley WA, Wang LZ, Reuillon T, Golding BT, Cano C, Newell DR, Noble ME, Wedge SR, Endicott JA, Griffin RJ. Anscombe E, et al. Chem Biol. 2015 Sep 17;22(9):1159-64. doi: 10.1016/j.chembiol.2015.07.018. Epub 2015 Aug 27. Chem Biol. 2015. PMID: 26320860 Free PMC article.
An inhibitor's-eye view of the ATP-binding site of CDKs in different regulatory states.
Echalier A, Hole AJ, Lolli G, Endicott JA, Noble ME. Echalier A, et al. ACS Chem Biol. 2014 Jun 20;9(6):1251-6. doi: 10.1021/cb500135f. Epub 2014 Apr 10. ACS Chem Biol. 2014. PMID: 24669831 Free PMC article.
The CDK9 C-helix exhibits conformational plasticity that may explain the selectivity of CAN508.
Baumli S, Hole AJ, Noble ME, Endicott JA. Baumli S, et al. ACS Chem Biol. 2012 May 18;7(5):811-6. doi: 10.1021/cb2004516. Epub 2012 Feb 10. ACS Chem Biol. 2012. PMID: 22292676 Free PMC article.
The CDK9 tail determines the reaction pathway of positive transcription elongation factor b.
Baumli S, Hole AJ, Wang LZ, Noble ME, Endicott JA. Baumli S, et al. Structure. 2012 Oct 10;20(10):1788-95. doi: 10.1016/j.str.2012.08.011. Epub 2012 Sep 6. Structure. 2012. PMID: 22959624 Free PMC article.
14 results
Jump to page
Feedback